Alkem Laboratories' Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- Alkem Laboratories Ltd reported a 5.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.9%.
- Its expenses for the quarter were down by 5.1% QoQ and up 11.3% YoY.
- The net profit decreased 16.2% QoQ and increased 1.9% YoY.
- The earnings per share (EPS) of Alkem Laboratories Ltd stood at 53.19 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 3879.92 | 4104.68 | 3467.27 | -5.5% | 11.9% |
Total Expenses | 3045.93 | 3208.85 | 2736.20 | -5.1% | 11.3% |
Profit Before Tax | 781.20 | 895.83 | 731.07 | -12.8% | 6.9% |
Tax | 127.67 | 116.23 | 90.28 | 9.8% | 41.4% |
Profit After Tax | 653.03 | 779.11 | 640.79 | -16.2% | 1.9% |
Earnings Per Share | 53.19 | 63.99 | 52.34 | -16.9% | 1.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alkem Laboratories Ltd is a major pharmaceutical company headquartered in India, known for its extensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates in the healthcare industry, primarily focusing on the development, manufacture, and sale of pharmaceutical products. Alkem Laboratories is recognized for its strong presence in both domestic and international markets, providing a wide array of medications across various therapeutic areas. As of the latest available information, there are no specific recent major developments provided, but the company is generally engaged in continuous research and development to enhance its product offerings in the competitive pharmaceutical landscape.
Revenue
For the quarter ended in Q3FY26, Alkem Laboratories Ltd reported a total income of ₹3879.92 crores. This represents a decrease of 5.5% compared to the previous quarter (Q2FY26), where the total income was ₹4104.68 crores. However, when compared year-over-year, there was an increase of 11.9% from Q3FY25, where total income stood at ₹3467.27 crores. The year-over-year growth in total income suggests an upward trend in revenue compared to the same quarter in the previous year, despite a sequential quarter decline.
Profitability
In Q3FY26, the company recorded a profit before tax of ₹781.20 crores, which is a decline of 12.8% from the previous quarter's profit before tax of ₹895.83 crores. On a year-over-year basis, there is an increase of 6.9% from Q3FY25, where the profit before tax was ₹731.07 crores. The tax expenses for Q3FY26 were ₹127.67 crores, showing an increase of 9.8% from the previous quarter and 41.4% from the same quarter last year, which was ₹90.28 crores. Consequently, the profit after tax for Q3FY26 was ₹653.03 crores, reflecting a decrease of 16.2% from the previous quarter and a slight increase of 1.9% year-over-year. The earnings per share for this quarter was ₹53.19, down by 16.9% from ₹63.99 in Q2FY26, and up by 1.6% from ₹52.34 in Q3FY25.
Operating Metrics
The total expenses for Alkem Laboratories in Q3FY26 were ₹3045.93 crores, a decrease of 5.1% from ₹3208.85 crores in the previous quarter. Year-over-year, the expenses increased by 11.3% from ₹2736.20 crores in Q3FY25. The decline in expenses on a quarter-over-quarter basis is in line with the decrease in total income. Despite the quarter-over-quarter decline in both income and expenses, the year-over-year increase in these metrics indicates an overall growth trend when compared to the same quarter in the previous year. The financial data for Q3FY26 shows significant changes in the company's operational metrics, reflecting the dynamics of the pharmaceutical industry.